All In MedTech

Device Trial Radar · NCT05905835

Treatment of PAF With the Synaptic System

Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation With the Synaptic Compliant Cryoablation Balloon and System

Last checked: Nov 20, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

128

Actual

Start

Sep 20, 2023

Primary completion

Nov 5, 2025

Study completion Dec 5, 2025

Sponsor

Lead sponsor
Synaptic Medical CorporationNot on our public-company list
Sponsor type
Industry
First posted
Jun 15, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Enrolled subjects will be treated with the Synaptic Cryoablation System. Treatment will include cryoablation of the pulmonary veins to achieve PVI. All subjects will be followed for twelve (12) months after completion of the index ablation procedure.

Conditions

  • Paroxysmal Atrial Fibrillation

Interventions

  • Synaptic Cryoablation SystemDevice

    The Synaptic Cryo Balloon must be used to isolate all targeted pulmonary veins. Entrance block will be confirmed in all targeted pulmonary veins (PVs) after a 20-minute waiting period or provocative testing with adenosine or isoproterenol. Any additional ablation in the LA beside PV isolation is not allowed in this protocol. Additional ablation of the cavo-tricuspid isthmus (CTI) with a conventional market-approved RF catheter is allowed only in case a typical atrial flutter is documented in prior patient history or occurs during the case (either spontaneously or inducible).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. safety - proportion of subjects who experienced device/procedure related Major Adverse Events (MAEs)Time frame: 6 months
  2. EffectivenessTime frame: 12 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Banner University Medical Center

    Phoenix, Arizona

  • Dignity Health Arizona Research Enterprise

    Phoenix, Arizona

  • St. Bernard's Heart & Vascular

    Jonesboro, Arkansas

7 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.